Azitra, Inc. (AZTR)
Largest Insider Buys in Sector
AZTR Stock Price History Chart
AZTR Stock Performance
About Azitra, Inc.
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human …
Insider Activity of Azitra, Inc.
Over the last 12 months, insiders at Azitra, Inc. have bought $115,514 and sold $0 worth of Azitra, Inc. stock.
On average, over the past 5 years, insiders at Azitra, Inc. have bought $7.3M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Salva Francisco D. (President and CEO) — $99,990. Staskey Norm (Chief Financial Officer) — $11,024. Whitfill Travis (Chief Operating Officer) — $4,500.
The last purchase of 47,600 shares for transaction amount of $10,034 was made by Staskey Norm (Chief Financial Officer) on 2024‑03‑29.
List of Insider Buy and Sell Transactions, Azitra, Inc.
| 2024-03-29 | Chief Financial Officer | 47,600 0.2506% | $0.21 | $10,034 | -87.28% | |||
| 2024-02-13 | President and CEO | 333,300 2.4975% | $0.30 | $99,990 | -92.59% | |||
| 2024-02-13 | Chief Operating Officer | 15,000 0.1124% | $0.30 | $4,500 | -92.59% | |||
| 2024-02-13 | Chief Financial Officer | 3,300 0.0247% | $0.30 | $990 | -92.59% | |||
| 2023-06-21 | 10 percent owner | 2.3M – | $3.15 | $7.24M | -73.83% | |||
| 2023-06-21 | 10 percent owner | 2.3M – | $3.15 | $7.24M | -73.83% |